secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001819790-26-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus appoints former Allergan CEO David Pyott to Board of Directors
---------------------------------------------------------------------

- Pyott appointed as Class III director effective Feb 18, 2026; term expires at 2026 annual meeting.
- He chairs Commercial Committee and serves on Nominating and Compensation Committees; deemed independent.
- Initial equity grant target $540,000 (50% options, 50% RSUs) under non-employee director policy.
- Pyott served as Allergan CEO for 17 years, grew revenue from ~$1B to >$7B; also on Alnylam and Pliant boards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000005/0001819790-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000005/tars-20260218.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer